Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UCPVax · 1 trial · 1 indication
Rate for patients alive at 18 months post-randomization
| Arm | Type | Description |
|---|---|---|
| Experimental Arm A | EXPERIMENTAL | UCPVax + Pembrolizumab + Standard of care |
| Experimental Arm B | EXPERIMENTAL | UCPVax + Standard of care |
| Control Arm C | OTHER | Standard of care |
| Name | Type | Description |
|---|---|---|
| UCPVax | DRUG | Priming : UCPVax (two helper peptides UCP2 and UCP4 + Montanide ISA51) at 0.5 mg subcutaneously at day 1, 8, 15, 29, 36 and 43 Boost : UCPVax at 0.5 mg subcutaneously one month after priming and then every 8 weeks for 12 months maximum |
| Pembrolizumab | DRUG | 400 mg/m1 every 6 weeks since day 1 until disease progression or unacceptable toxicity for a maximum of 1 year |
| Temozolomide | DRUG | 150-200 mg/m2/day x 5 days per month x 6 months according to best standard of care starting at day 1 of week 1 (with vaccine 1 of UCPVax). Additional treatment with NOVO-TTF200A will be allowed. |
Inclusion Criteria: 1. Male or female, age ≥ 18 with informed consent signed 2. Patient with a confirmed histological diagnosis of non-mutated IDH primary glioblastoma (surgical resection or biopsy). 3. Tumor with unmethylated MGMT promoter status 4. Patients having completed the concomitant phase ...
UCPVax is an investigational small molecule being studied for the treatment of Primary Glioblastoma. It is currently in Phase 2 clinical development as an adjuvant therapy for patients with unmethylated MGMT glioblastoma. The drug is being evaluated in combination with standard treatment, with or without pembrolizumab.
UCPVax is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting a Phase 2 clinical trial of UCPVax in patients with Primary Glioblastoma.
UCPVax is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 2 trial is evaluating UCPVax as an adjuvant therapy for Primary Glioblastoma.
UCPVax is being studied in one active Phase 2 clinical trial with the identifier NCT07347210. This trial evaluates UCPVax with or without pembrolizumab combined with standard treatment as adjuvant therapy in patients with unmethylated MGMT glioblastoma. The trial is planned to enroll 98 participants in France.
Yes, the Phase 2 clinical trial of UCPVax in Primary Glioblastoma is randomized and controlled. The trial is not double-blind, meaning participants and investigators know which treatment is being administered. The study is biomarker-selected, focusing on patients with unmethylated MGMT glioblastoma.